Fatty-liver drugs may have a second front

The obesity-drug boom is being measured against the wrong ruler. Fatty liver disease is not a weight problem wearing a liver label. It is a liver problem that happens to track with weight, and the drugs racing through MASH trials are now being asked which one they actually do.

A mediation analysis published in HEP this month, re-reading a phase 2 trial of survodutide in 170 patients with F2-F3 fibrosis, suggests the answer splits by endpoint. Liver fat shrank mostly because patients lost weight: 77.4% of the FibroScan CAP reduction and 58.2% of the MRI-PDFF reduction rode along with pounds shed. Liver inflammation and fibrosis did not. The HEP paper's authors estimate 66.7% of MASH resolution and 71.8% of MASH improvement were weight-driven, but only 36.3% of fibrosis improvement was, leaving roughly 63.7% unattributed to weight loss. The straightforward reading is that the liver is being treated twice: once through the body's fat, and once through something the drug is doing to the liver itself, plausibly via direct glucagon-receptor activity.

The mechanism is a category, not just a side effect. MASH patients who cannot lose enough weight through diet, exercise, or current obesity drugs are the population standard coverage skips. If the second front holds up in larger trials, the disease stops looking like a willpower story and starts looking like a drug-target story. The catch is in the design: 170 patients, pooled dose arms, post-hoc, and a mediation model the HEP paper's authors themselves call suggestive. One trial does not move a class. But it does name the question the next trials have to answer.